Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725444 | 0.72 | PI4KA (0.39) | PDE2A | |
| SCHEMBL17680109 | 0.69 | ALDH1A1 (0.38) | ALDH1A1HPGD | |
| SCHEMBL14725446 | 0.68 | PDE2A (0.41) | PDE2AALDH1A1HPGDTYMS | |
| SCHEMBL11845691 | 0.67 | LMNA (0.34) | MAPT | |
| SCHEMBL14725451 | 0.67 | PDE4A (0.32) | — | |
| SCHEMBL26354792 | 0.66 | KMT2A (0.36) | PDE2AALDH1A1HPGDMAPT | |
| SCHEMBL10037062 | 0.66 | YTHDC1 (0.46) | — | |
| SCHEMBL12820948 | 0.65 | PDE2A (0.41) | PDE2AALDH1A1HPGDMAPTTYMS | |
| SCHEMBL17282460 | 0.63 | CDK2 (0.44) | PDE2AMAPT | |
| SCHEMBL14725453 | 0.62 | YTHDC1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | PDE2A 4619/4885ALDH1A1 1169/4885HPGD 3957/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | PDE2A 4600/4885ALDH1A1 971/4885HPGD 3797/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | PDE2A 4600/4885ALDH1A1 971/4885HPGD 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.